Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | IDO1 | P14902 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | GSK3B | P49841 | 1/20 | 0.53 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28022449 | 0.88 | ALDH1A1 (0.52) | RAB9AIDO1ALDH1A1MAPTGSK3B | |
| SCHEMBL1555636 | 0.86 | ALDH1A1 (0.59) | RAB9AIDO1ALDH1A1MAPTAKR1C3 | |
| SCHEMBL5235557 | 0.85 | IDO1 (0.56) | RAB9AIDO1ALDH1A1MAPTAKR1C3 | |
| SCHEMBL7729899 | 0.85 | ALDH1A1 (0.58) | RAB9AIDO1ALDH1A1MAPTAKR1C3 | |
| SCHEMBL15388876 | 0.83 | RAB9A (0.61) | RAB9AIDO1ALDH1A1MAPTAKR1C3 | |
| SCHEMBL6141237 | 0.83 | ALDH1A1 (0.56) | RAB9AIDO1ALDH1A1MAPTAKR1C3 | |
| SCHEMBL5016761 | 0.83 | RAB9A (0.54) | RAB9AIDO1ALDH1A1MAPTAKR1C3 | |
| Water SCHEMBL8424505 | 0.83 | RAB9A (0.54) | RAB9AIDO1ALDH1A1MAPTAKR1C3 | |
| SCHEMBL11094410 | 0.83 | ALDH1A1 (0.56) | RAB9AIDO1ALDH1A1MAPTAKR1C3 | |
| SCHEMBL8697546 | 0.83 | RAB9A (0.54) | RAB9AIDO1ALDH1A1MAPTAKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-5170707-A | — | — | None | — | — | JP | disclosed |
| US-8883824-B2 | 3-(4-aminophenyl)-2-furancarboxylic acid derivative and pharmaceutically acceptable salt thereof | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2014-11-11 | — | — | US | disclosed |
| EP-2431362-A1 | 3-(4-AMINOPHENYL)-2-FURANCARBOXYLIC ACID DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2012-03-21 | — | — | EP | disclosed |
| US-20120059012-A1 | 3-(4-AMINOPHENYL)-2-FURANCARBOXYLIC ACID DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-03-08 | — | — | US | disclosed |
| US-7045619-B2 | 2-(pyrazol-3-yl)carbapenem derivatives | SMITHKLINE BEECHAM P.L.C. (GB) | 2006-05-16 | — | — | US | disclosed |
| US-6686353-B1 | PREVENTING BLOOD MONOCYTES AND LYMPHOCYTES FROM INFILTRATING TISSUE | TEIJIN INTELLECTUAL PROPERTY CENTER LIMITED (JP) | 2004-02-03 | — | — | US | disclosed |
| US-20030166923-A1 | 2-(pyrazol-3-yl)carbapenem derivatives | SMITHKLINE BEECHAM P.L.C. | 2003-09-04 | — | — | US | disclosed |
| EP-0725783-B1 | 2-(PYRAZOL-3-YL)CARBAPENEM DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 2002-12-18 | — | — | EP | disclosed |
| US-20020147333-A1 | 2-(pyrazol-3-yl)carbapenem derivatives | SMITHKLINE BEECHAM P.L.C. | 2002-10-10 | — | — | US | disclosed |
| EP-0914319-B1 | DIARYLALKYL CYCLIC DIAMINE DERIVATIVES AS CHEMOKINE RECEPTOR ANTAGONISTS | TEIJIN LTD (JP) | 2001-11-21 | — | — | EP | disclosed |
| US-4487927-A | BACTERICIDES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1984-12-11 | — | — | US | disclosed |
| US-4477447-A | ANTIBIOTIC, BACTERICIDE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1984-10-16 | — | — | US | disclosed |
| US-4473578-A | ACID, ESTER OR SALT DERIVATIVES OF MERCAPTO CARBAPENEMS | BEECHAM GROUP LIMITED (GB) | 1984-09-25 | — | — | US | disclosed |
| EP-0115308-A2 | 2-Unsaturated alkylthio-pen-2-em-3-carboxylic acids and process for preparing substituted 2-thioxopenams and 2-substituted thiopenems | MERCK & CO. INC. (US) | 1984-08-08 | — | — | EP | disclosed |
| EP-0055990-A1 | Beta-lactam antibiotics, their preparation and use | BEECHAM GROUP PLC (GB) | 1982-07-14 | — | — | EP | disclosed |
| US-4309346-A | INTERMEDIATES FOR AMINO ACID DERIVATIVE ANTIBIOTICS | MERCK & CO., INC. (US) | 1982-01-05 | — | — | US | disclosed |
| EP-0024832-A1 | Beta-lactam antibiotics, their preparation, pharmaceutical compositions containing them and their preparation | BEECHAM GROUP PLC (GB) | 1981-03-11 | — | — | EP | disclosed |
| US-4251517-A | FUNGICIDES | CIBA-GEIGY CORPORATION (US) | 1981-02-17 | — | — | US | disclosed |
| EP-0003415-A2 | Beta-Lactam compounds, processes for their preparation,compositions containing them and intermediates of use in their preparation | GLAXO GROUP LIMITED (GB) | 1979-08-08 | — | — | EP | disclosed |
| EP-0000636-A1 | Penem compounds, processes for their preparation, their use in pharmaceutical compositions and azetidinones used in their preparation | GLAXO GROUP LIMITED (GB) | 1979-02-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059012-A1 | 3-(4-AMINOPHENYL)-2-FURANCARBOXYLIC ACID DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ACSL3, SLCO4C1, SLC38A7 | RAB9A 531/4885IDO1 2140/4885ALDH1A1 96/4885 |
| US-20020147333-A1 | 2-(pyrazol-3-yl)carbapenem derivatives | DPEP1, DHPS, JMJD6 | RAB9A 1275/4885IDO1 1498/4885ALDH1A1 308/4885 |
| US-20030166923-A1 | 2-(pyrazol-3-yl)carbapenem derivatives | DHPS, DPEP1, JMJD6 | RAB9A 1442/4885IDO1 1282/4885ALDH1A1 343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.